Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026

MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets MUC16 is highly and stably expressed in the most aggressive and most common subtypes of endometrial cancer Findings support Whitehawk's development of MUC16-directed ADC, HWK-016, currently being explored in Phase 1 for advanced ovarian and endometrial cancers MORRISTOWN, N.J., April 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today presented three posters from a real-world analysis supporting the therapeutic potential of targeting mucin 16 (MUC16) with a next-generation ADC for the treatment of ovarian and endometrial cancers at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women's Cancer, being held April 10-13, 2026, in San Juan, Puerto Rico.